How to Help Your Patients Find Afrezza in Stock: A Provider's Guide

Your Patient Needs Afrezza — Here's How to Get It to Them

You've determined that Afrezza 180 Titration Pack- 60, 60, 60 is the right fit for your patient. The spirometry is done, the prescription is written, and then you hear back: the pharmacy doesn't have it. This scenario plays out regularly for providers who prescribe inhaled insulin, and it doesn't have to derail your patient's treatment plan.

This guide provides practical strategies to help your patients access Afrezza despite ongoing availability challenges.

Current Availability Landscape

Afrezza is actively manufactured by MannKind Corporation and remains on the market. However, availability at the retail pharmacy level is inconsistent. Key factors:

• Low stocking rates: The majority of chain pharmacies (CVS, Walgreens, Rite Aid) do not routinely stock Afrezza. It represents a very small percentage of insulin prescriptions, so pharmacies don't keep it on hand.
• Specialty distribution: Afrezza is primarily distributed through specialty pharmacy channels. Patients sent to a standard retail pharmacy will often face delays or unavailability.
• Regional variation: Availability varies significantly by geography. Urban areas with endocrinology practices tend to have better access than rural regions.

Why Patients Can't Find Afrezza

Understanding the barriers helps you address them proactively:

1. The prescription goes to the wrong pharmacy. If sent to a retail pharmacy that doesn't stock Afrezza, the patient faces a dead end or a multi-day wait for special ordering.
2. Insurance requires specialty pharmacy dispensing. Some plans mandate that Afrezza be filled through a designated specialty pharmacy, but patients may not know this.
3. Prior authorization delays. Even when the pharmacy can obtain Afrezza, PA processing can delay dispensing by days to weeks.
4. Patient doesn't know where to look. Without guidance, patients default to their usual pharmacy and give up after one failed attempt.

What Providers Can Do

1. Build a Specialty Pharmacy Network

Identify two to three specialty pharmacies in your area that reliably stock Afrezza. Maintain this list in your practice's EHR or resource guide. When prescribing Afrezza, send the prescription directly to one of these pharmacies rather than letting the patient choose their default retail pharmacy.

2. Use Real-Time Availability Tools

Medfinder for Providers allows you or your staff to check which pharmacies near your patient currently have Afrezza in stock. This takes minutes and can save your patient days of frustration.

3. Proactively Manage Prior Authorization

Submit prior authorization requests at the time of prescribing, not after the pharmacy flags a rejection. Include documentation of:

• Clinical rationale for inhaled insulin (needle phobia, injection site lipodystrophy, adherence issues)
• Spirometry results confirming adequate lung function
• Prior trials of injectable insulin, if step therapy is required

4. Enroll Patients in AfrezzaAssist

MannKind's AfrezzaAssist program provides access support including pharmacy identification, coverage assistance, and co-pay cards. Encourage your patients to enroll at the time of prescribing — don't wait until they hit a barrier.

5. Discuss Alternatives Upfront

At the time you prescribe Afrezza, briefly discuss what the backup plan would be if the patient can't fill it. Having a contingency prescription for insulin lispro or insulin aspart on file — with clear instructions not to fill it unless needed — gives the patient a safety net.

Alternative Rapid-Acting Insulins

If Afrezza truly cannot be obtained, the following injectable alternatives offer comparable mealtime glucose control:

• Insulin lispro (generic Humalog): Widely available, affordable with generic pricing. Onset 15-30 minutes.
• Insulin aspart (generic NovoLog): Similarly available and affordable. Onset 15-30 minutes.
• Fiasp (fast-acting insulin aspart): Ultra-rapid onset (~2.5 minutes). Closest to Afrezza's speed profile. Brand-only pricing.
• Apidra (insulin glulisine): Another option with rapid onset. Less commonly prescribed but available.

Dose conversion from inhaled to injectable insulin requires careful calculation. Refer to the Afrezza prescribing information for the conversion table.

Final Thoughts

The gap between prescribing Afrezza and your patient actually receiving it is often wider than it should be. By proactively routing prescriptions to specialty pharmacies, using availability tools like Medfinder for Providers, and enrolling patients in support programs, you can close that gap significantly.

For the patient-facing version of this guidance, share our article on how to find Afrezza in stock. For a broader view of the supply situation, see our provider shortage briefing.